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to Rmp (an immunogenic protein against which antibodies have a counter-effective blocking activity) affords protection [10] . However, in the absence of a recognized and reproducible state of immunity in humans, the determinants of immune protection have not been defined.
Several new developments, however, now combine to bring hope that an effective vaccine against N. gonorrhoeae is indeed on the horizon. The first of these, is the recent findings that N. gonorrhoeae proactively manipulates the host immune response for its own benefit, by selectively eliciting innate host defenses that it can survive while concomitantly suppressing adaptive immune responses that would eliminate it [11] . Several mechanisms have been described that contribute to this ability, including inactivation of T helper cells [12] , modulation of dendritic cells or macrophages [13, 14] and upregulation of IL-10, TGF-β and type 1 regulatory T cells [15] . These findings reveal new understandings of immunity to N. gonorrhoeae and suggest that novel approaches to reverse gonococcus-induced immunosuppression might be fruitful; moreover they inform new strategies for vaccine development. Second, animal models have been developed for preclinical evaluation of vaccine candidates; it is noteworthy in this context that all previous attempts to create gonococcal vaccines lacked any such in vivo models in which to test candidates. The estradiol-treated female mouse model [16] has now been applied to this effort [17] , and further refinements of the model using transgenic mice that express various human factors involved in gonococcal pathogenesis afford scope for more detailed analysis of the mechanisms whereby immune protection can be attained [10] . Third, efforts are now underway to apply proteomics technology to the discovery of novel, conserved surface antigens shared by different strains of N. gonorrhoeae [18] . Already some initial candidate antigens have been identified, although these have not yet been evaluated in animal models of protection. Nevertheless, these findings raise the exciting prospect that protective immunity might not necessarily depend on previously known, highly variable major antigens, whose diverse epitopes and variable expression appear to be used by N. gonorrhoeae in effect to confuse the immune system. Finally, it has been reported that subjects in New Zealand, who had been immunized against Neisseria meningitidis using the MeNZB vaccine (which is no longer available), were less likely to be diagnosed with gonorrhea over the ensuing 10 years than unimmunized subjects [19] . While the degree of protection was modest (∼31%), this finding represents the first report of protective immunity against gonorrhea in humans. Further investigation of the antibodies developed in immunized subjects and their specificity for gonococcal antigens can be expected to yield valuable insights. Interestingly, the antigen components of the MeNZB vaccine (the outer membrane vesicles of a group B strain of N. meningitidis) are used in the new group B meningococcal vaccine, Bexsero R , now licensed by GlaxoSmithKline (Rixensart, Belgium). Thus it will be important to confirm and extend the New Zealand findings in a wider geographical context.
Results obtained from immunization of mice indicate that both antibodies (IgG and/or IgA) and IFN-γ are required for immunity to N. gonorrhoeae [17] , but the mechanism of protection is uncertain, and it cannot be assumed that findings from mice will necessarily apply to humans. Unfortunately, no other animal model is available for this exclusively human infection, as nonhuman primates (with the possible exception of chimpanzees) cannot be infected with N. gonorrhoeae. Nevertheless, it should be possible to evaluate immune responses to vaccination in nonhuman primates in order to determine whether similar responses are elicited in a species that is more closely related to humans. Furthermore, it is possible that responses and mechanisms of immune defense may be different in males and females, but in the absence of an animal model of male infection this has not been examined. Hitherto, attention has been focused on complement-mediated bacteriolysis or opsonophagocytosis as mechanisms of defense, as these can be readily demonstrated in vitro, and because it is known that immunity to N. meningitidis depends on complement. Neutrophils are abundant in the purulent exudate typical of symptomatic gonorrhea, but it is now clear that N. gonorrhoeae can at least partially survive phagocytosis by neutrophils [20] . However, it cannot be assumed that these mechanisms, which may be relevant in female upper tract infection or in disseminated gonococcal infection (a rare complication in both sexes), are applicable in uncomplicated gonococcal cervicitis or urethritis. Other mechanisms of defense can be envisaged at mucosal surfaces, including inhibition of adherence and invasion of the epithelium, and inhibition of metabolic functions. The goal of vaccination should also be considered: whether the objective is to prevent the serious effects of upper tract infection in females (tubal scarring, hence infertility and increased risk of ectopic pregnancy, and pelvic inflammatory disease) which are difficult to quantify clinically and may have multiple etiological causes, or to prevent cervical gonococcal infection in the first place. Vaccination of men must also be considered, not only to prevent infection and disease, but because they serve as the essential vectors of infection in women and are therefore important for epidemiological control of the disease.
The scientific stage is therefore set for significant advances in comprehending immunity to N. gonorrhoeae and making an effective vaccine against gonorrhea a reality. Much work remains to be done, and it will take time to accomplish, but the results should yield fascinating insights into an extremely well adapted human pathogen. The limitations are whether there is the socio-political will to achieve this and make the necessary funding available.
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